Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | HPGD | P15428 | 5/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | RBP4 | P02753 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8189624 | 0.84 | KDM4E (0.37) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL8253879 | 0.83 | KDM4E (0.46) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL10164411 | 0.83 | KDM4E (0.44) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL4256917 | 0.83 | ALDH1A1 (0.66) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL8246398 | 0.82 | ALDH1A1 (0.53) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL8253049 | 0.81 | ALDH1A1 (0.52) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL20064736 | 0.81 | KDM4E (0.52) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL8247369 | 0.79 | PIK3CG (0.57) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL4224849 | 0.79 | KDM4E (0.51) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL20064735 | 0.77 | ALDH1A1 (0.49) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835441-B2 | Heterobicyclic metalloprotease inhibitors | AMGEN INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-7795245-B2 | Heterobicyclic metalloprotease inhibitors | Atlantos Pharmaceuticals Holding, Inc. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795245-B2 | Heterobicyclic metalloprotease inhibitors | Atlantos Pharmaceuticals Holding, Inc. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| EP-2102211-A2 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | Alantos Pharmaceuticals Holding, Inc. (US) | 2009-09-23 | — | — | EP | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20080176870-A1 | Heterobicyclic metalloprotease inhibitors | NOLTE BERT | 2008-07-24 | — | — | US | disclosed |
| US-20080176870-A1 | Heterobicyclic metalloprotease inhibitors | NOLTE BERT | 2008-07-24 | — | — | US | disclosed |
| US-20080176870-A1 | Heterobicyclic metalloprotease inhibitors | NOLTE BERT | 2008-07-24 | — | — | US | disclosed |
| WO-2008063671-A2 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008063671-A2 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| WO-2006128184-A2 | PYRIMIDINE OR TRIAZINE FUSED BICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS-PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176870-A1 | Heterobicyclic metalloprotease inhibitors | ADAM17, ADAM8, ADAM10 | KDM4E 2588/4885ALDH1A1 2279/4885HPGD 414/4885 |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | MMP13, TIMP3, MMP3 | KDM4E 2058/4885ALDH1A1 1806/4885HPGD 313/4885 |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | MMP13, TIMP3, MMP3 | KDM4E 2058/4885ALDH1A1 1806/4885HPGD 313/4885 |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | KDM4E 2058/4885ALDH1A1 1806/4885HPGD 313/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | KDM4E 2058/4885ALDH1A1 1806/4885HPGD 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.